Ark Therapeutics Plc said that the European Medicines Agency has accepted its application for a marketing authorisation to launch a novel gene therapy to treat brain cancer. The application is one of the first in a new group of advanced therapies that are being regulated under European legislation that took effect on 30 December 2008. Ark announced the start of the regulatory review of its product, Cerepro, on 6 January 2009.
